Mechanisms of chemotherapy resistance in ovarian cancer

Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz, Mylena, Wabel, Emma, Mitchell, Kerry, Horibata, Sachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255249/
https://www.ncbi.nlm.nih.gov/pubmed/35800369
http://dx.doi.org/10.20517/cdr.2021.147
_version_ 1784740886425370624
author Ortiz, Mylena
Wabel, Emma
Mitchell, Kerry
Horibata, Sachi
author_facet Ortiz, Mylena
Wabel, Emma
Mitchell, Kerry
Horibata, Sachi
author_sort Ortiz, Mylena
collection PubMed
description Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.
format Online
Article
Text
id pubmed-9255249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-92552492022-07-06 Mechanisms of chemotherapy resistance in ovarian cancer Ortiz, Mylena Wabel, Emma Mitchell, Kerry Horibata, Sachi Cancer Drug Resist Review Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs. OAE Publishing Inc. 2022-04-03 /pmc/articles/PMC9255249/ /pubmed/35800369 http://dx.doi.org/10.20517/cdr.2021.147 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Ortiz, Mylena
Wabel, Emma
Mitchell, Kerry
Horibata, Sachi
Mechanisms of chemotherapy resistance in ovarian cancer
title Mechanisms of chemotherapy resistance in ovarian cancer
title_full Mechanisms of chemotherapy resistance in ovarian cancer
title_fullStr Mechanisms of chemotherapy resistance in ovarian cancer
title_full_unstemmed Mechanisms of chemotherapy resistance in ovarian cancer
title_short Mechanisms of chemotherapy resistance in ovarian cancer
title_sort mechanisms of chemotherapy resistance in ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255249/
https://www.ncbi.nlm.nih.gov/pubmed/35800369
http://dx.doi.org/10.20517/cdr.2021.147
work_keys_str_mv AT ortizmylena mechanismsofchemotherapyresistanceinovariancancer
AT wabelemma mechanismsofchemotherapyresistanceinovariancancer
AT mitchellkerry mechanismsofchemotherapyresistanceinovariancancer
AT horibatasachi mechanismsofchemotherapyresistanceinovariancancer

Ejemplares similares